First-line nivolumab-cabozantinib improves PFS, OS, ORR in advanced clear cell RCC
09 Nov 2020
bởiRoshini Claire Anthony
The combination of nivolumab and cabozantinib in the first-line setting conferred greater survival outcomes and responses compared with sunitinib in patients with clear cell advanced renal cell carcinoma (RCC), results of the phase III CheckMate 9ER trial showed.
First-line nivolumab-cabozantinib improves PFS, OS, ORR in advanced clear cell RCC
09 Nov 2020